C4 Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
C4T reported Q2 2026 revenue of $6.6M (vs. $6.5M YoY), driven by a new Roche degrader-antibody conjugate collaboration that generated a $20M upfront payment in May 2026. The company raised $33.5M net in Q2 via its ATM program. Net loss improved to $23.6M (vs. $26.0M YoY). Cash position strengthened to $300.4M as of June 30, 2026, with runway projected through end of 2028. Cemsidomide Phase 2 MOMENTUM trial on track for Q1 2027 enrollment completion; ORR data expected H2 2027.
Why this rating
Roche partnership validates platform; $20M upfront is ~20% of market cap but modest relative to $300M cash. Capital raise extends runway 2+ years. Clinical progress routine for stage. Moderate boost but not trajectory-altering.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.